Stay updated on Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.
Latest updates to the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page
- CheckyesterdayChange DetectedRevision label on the page updated from `Revision: v3.3.3` to `Revision: v3.3.4`.SummaryDifference0.1%
- Check8 days agoChange DetectedThe study page now shows 'Results Submitted' in place of 'No Results Posted', indicating that results have been submitted.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedAdded a Locations section with Texas as a study site and updated the revision to v3.3.3; the old Texas Locations label and the HHS Vulnerability Disclosure link were removed.SummaryDifference0.2%
- Check50 days agoChange DetectedSite revision updated from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%
- Check58 days agoChange DetectedRemoved the government funding notice warning that information may be out of date and transactions may not be processed due to a lapse in appropriations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
- Check72 days agoChange DetectedThe differences are cosmetic UI updates and an updated last updated date, with core trial information unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%
Stay in the know with updates to Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Relapsed Myeloma Post-Transplant Clinical Trial page.